Skip to main content
Fig. 4 | Cardiovascular Diabetology

Fig. 4

From: The risk of new-onset atrial fibrillation in patients with type 2 diabetes mellitus treated with sodium glucose cotransporter 2 inhibitors versus dipeptidyl peptidase-4 inhibitors

Fig. 4

Subgroup analysis of forest plot of HR for SGLT2i versus DPP4i among T2DM patients with/without previous DPP4i exposure, treated with different SGLT2i or different SGLT2i dosages after IPTW. The benefits of SGLT2i over DPP4i in lowering the risk of incident AF persisted with previous DPP4i-exposure SGTL2i user, different SGLT2i (dapagliflozin or empagliflozin) and both low- (empagliflozin 10 mg or dapagliflozin 5 mg once daily) and standard-dose (empagliflozin 25 mg or dapagliflozin 10 mg once daily) SGLT2i treatment. The abbreviations as in Fig. 3

Back to article page

Cardiovascular Diabetology

ISSN: 1475-2840